Cyber Swan Sale

50% Off Elite

Days

Hours

Mins

Sec

Get our most powerful screeners, new charting tools, and the fastest ad-free experience at our best price ever. One last chance.

JAGX

Jaguar Health Inc

Dec 02 • 12:42PM ET

1.17

-0.00 -0.43 %

Healthcare • Biotechnology • USA • NASD

Today, 9:09 AMJaguar Health announced today that its Napo Therapeutics unit submitted a request to the EMA’s CVMP for scientific advice on pursuing EU approval of Canalevia for treating general diarrhea in dogs, with a review targeted for March 2026.

Peers: VSTM AMRN MNOV CHRS NBIX ENTA TGTX MRSN KPTI ONCT

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-52.01	Insider Own	29.55%	Shs Outstand	3.69M	Perf Week	-7.87%
Market Cap	4.37M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	0.00%	Shs Float	2.63M	Perf Month	-39.69%
Enterprise Value	33.95M	PEG	-	EPS next Q	-	Inst Own	2.55%	Short Float	3.90%	Perf Quarter	-30.36%
Income	-40.29M	P/S	0.37	EPS this Y	92.27%	Inst Trans	2.65%	Short Ratio	0.73	Perf Half Y	-71.94%
Sales	11.79M	P/B	1.37	EPS next Y	94.36%	ROA	-74.66%	Short Interest	0.10M	Perf YTD	-95.37%
Book/sh	0.85	P/C	1.24	EPS next 5Y	85.48%	ROE	-370.95%	52W High	33.25 -96.48%	Perf Year	-95.30%
Cash/sh	0.94	P/FCF	-	EPS past 3/5Y	90.04% 86.61%	ROIC	-283.89%	52W Low	1.10 6.36%	Perf 3Y	-99.99%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.19% 15.14%	Gross Margin	62.78%	Volatility	9.42% 11.58%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	2.88	EPS Y/Y TTM	87.08%	Oper. Margin	-278.52%	ATR (14)	0.17	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	0.52	Sales Y/Y TTM	12.45%	Profit Margin	-341.90%	RSI (14)	30.80	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.81	EPS Q/Q	76.12%	SMA20	-22.73%	Beta	-0.42	Target Price	35.00
Payout	-	Debt/Eq	5.67	Sales Q/Q	-0.80%	SMA50	-37.37%	Rel Volume	6.62	Prev Close	1.17
Employees	49	LT Debt/Eq	1.52	Earnings	Nov 17 BMO	SMA200	-75.36%	Avg Volume	141.08K	Price	1.17
IPO	May 13, 2015	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	483,282	Change	-0.43%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-21	Initiated	Cantor Fitzgerald	Overweight	$5
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$2

Today 09:00AM	Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study (ACCESSWIRE)
Nov-24-25 09:00AM	Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones (ACCESSWIRE)
Nov-20-25 09:00AM	In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial (ACCESSWIRE) -8.15%
Nov-17-25 04:00PM	Jaguar Health Inc (JAGX) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Ongoing Challenges (GuruFocus.com) -8.03%
08:00AM	Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue (ACCESSWIRE)
09:00AM	Loading…
Nov-14-25 09:00AM	Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates (ACCESSWIRE)
Nov-13-25 09:00AM	Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting (ACCESSWIRE)
Oct-24-25 04:15PM	Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (ACCESSWIRE) +5.53%
Oct-06-25 09:00AM	Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID) (ACCESSWIRE)
Sep-30-25 09:00AM	FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease (ACCESSWIRE) +10.43%
Sep-25-25 09:00AM	Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs (ACCESSWIRE)
Sep-24-25 09:00AM	Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition (ACCESSWIRE) +6.97%
Sep-23-25 09:00AM	Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts (ACCESSWIRE)
Sep-21-25 09:10AM	Jaguar Health Completes Private Placement Deal (Insider Monkey)
Sep-05-25 09:00AM	Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts (ACCESSWIRE) +7.27%
09:00AM	Loading…
Aug-21-25 09:00AM	Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs (ACCESSWIRE)
Aug-19-25 04:15PM	Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders (ACCESSWIRE) -7.25%
09:00AM	Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID) (ACCESSWIRE)
Aug-14-25 08:00AM	Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue (ACCESSWIRE) -20.08%
Aug-12-25 09:00AM	Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates (ACCESSWIRE) +8.29%
Jul-16-25 07:00AM	Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream (GlobeNewswire)
Jul-10-25 08:30AM	Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs (ACCESSWIRE)
Jul-08-25 09:00AM	Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca (ACCESSWIRE)
Jun-30-25 09:00AM	Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient (ACCESSWIRE)
Jun-26-25 09:15AM	Jaguar Health to pursue approval of Canalevia in EU for general diarrhea in dogs (TipRanks) -7.19%
09:00AM	Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset (ACCESSWIRE)
Jun-25-25 09:00AM	Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs (ACCESSWIRE)
Jun-24-25 04:15PM	Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 (ACCESSWIRE) +12.96%
Jun-23-25 09:00AM	Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer (ACCESSWIRE)
Jun-17-25 09:00AM	Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts (ACCESSWIRE) -6.23%
07:00AM	Loading…
07:00AM	Presenting on Emerging Growth Conference 83 Day 2 on June 18; Register to live stream (GlobeNewswire)
Jun-11-25 10:00AM	First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs (ACCESSWIRE)
Jun-09-25 09:00AM	Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer (ACCESSWIRE) -6.40%
Jun-06-25 09:00AM	Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series (ACCESSWIRE)
May-21-25 08:00AM	Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -27.05%
May-20-25 09:15AM	First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID) (ACCESSWIRE)
May-16-25 07:09AM	Q1 2025 Jaguar Health Inc Earnings Call (Thomson Reuters StreetEvents) +6.91%
03:12AM	Jaguar Health Inc (JAGX) Q1 2025 Earnings Call Highlights: Navigating Challenges with Promising ... (GuruFocus.com)
May-15-25 02:30PM	Jaguar Health Reports First Quarter 2025 Financials (ACCESSWIRE) -10.86%
May-14-25 09:00AM	Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates (ACCESSWIRE) -6.52%
May-08-25 09:30AM	Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs (ACCESSWIRE) -20.95%
May-07-25 09:15AM	Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts (ACCESSWIRE)
Apr-30-25 08:15AM	Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients (ACCESSWIRE)
Apr-28-25 08:15AM	Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast (ACCESSWIRE)
Apr-17-25 09:00AM	Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress (ACCESSWIRE)
Apr-16-25 09:50AM	Jaguar Health to present results from OnTarget study in breast cancer patients (TipRanks) +9.81%
Apr-15-25 09:30AM	Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting (ACCESSWIRE)
Apr-08-25 08:30AM	Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product (ACCESSWIRE)
Apr-04-25 04:15PM	Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (ACCESSWIRE) +9.61%
Apr-01-25 04:15PM	Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE)
Mar-31-25 09:57AM	Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript (Seeking Alpha)
08:00AM	Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023 (ACCESSWIRE)
Mar-28-25 09:00AM	83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey (ACCESSWIRE) -7.06%
Mar-27-25 08:30AM	Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study (ACCESSWIRE)
Mar-26-25 11:00AM	Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts (ACCESSWIRE) -5.18%
09:25AM	Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE)
07:00AM	Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now (GlobeNewswire)
Mar-25-25 07:00AM	Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now (GlobeNewswire) -10.43%
Mar-18-25 08:30AM	Jaguar Health, Inc. Announces Reverse Stock Split (ACCESSWIRE) -47.76%
Mar-13-25 04:15PM	Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders (ACCESSWIRE) -6.46%
Feb-27-25 08:30AM	Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value (ACCESSWIRE) -15.59%
Feb-19-25 09:00AM	Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF) (ACCESSWIRE)
Feb-18-25 09:00AM	Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300 (ACCESSWIRE) +11.10%
07:00AM	Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now (GlobeNewswire)
Feb-13-25 09:05AM	Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts (ACCESSWIRE)
Feb-06-25 10:00AM	Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference (ACCESSWIRE)
Feb-03-25 09:30AM	Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025 (ACCESSWIRE) -5.02%
Jan-29-25 08:30AM	Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO (ACCESSWIRE) -5.12%
Jan-22-25 09:00AM	Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025 (ACCESSWIRE)
Jan-10-25 04:15PM	Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (ACCESSWIRE) -8.26% -7.38%
Jan-08-25 08:30AM	Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit and January 14 at Biotech Showcase (ACCESSWIRE) -7.63%
08:30AM	Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase (ACCESSWIRE)
Jan-07-25 10:00AM	Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum (ACCESSWIRE) -7.81%
Dec-19-24 09:00AM	Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications (ACCESSWIRE)
Dec-18-24 10:00AM	Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder (ACCESSWIRE) -8.51%
Dec-17-24 08:30AM	FDA Approves Orphan-Drug Designation for Jaguar Health's Crofelemer for Treatment of Diarrhea in Cholera (ACCESSWIRE)
Dec-16-24 07:00AM	FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES (PR Newswire) -5.50%
Dec-13-24 10:00AM	Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer (ACCESSWIRE)
Dec-12-24 09:00AM	Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS) (ACCESSWIRE) -23.82%
Dec-09-24 10:00AM	Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS) (ACCESSWIRE) +5.65%
Dec-06-24 08:30AM	U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins (ACCESSWIRE)
Dec-05-24 12:00PM	Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine (ACCESSWIRE)
Dec-04-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now (GlobeNewswire)
Dec-03-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now (GlobeNewswire)
Dec-02-24 10:00AM	Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs (ACCESSWIRE)
Nov-25-24 10:00AM	Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference (ACCESSWIRE)
Nov-22-24 08:45AM	Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs (ACCESSWIRE) +5.62%
Nov-19-24 09:30AM	Jaguar Health Family Company Napo Therapeutics Named 'Best Pharmaceuticals Innovator of the Year - Europe' (ACCESSWIRE)
Nov-14-24 02:08AM	Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com) +5.31%
Nov-13-24 08:00AM	Jaguar Health Reports Third Quarter 2024 Financial Results (ACCESSWIRE) -9.39%
Nov-11-24 08:30AM	Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates (ACCESSWIRE)
Nov-06-24 10:00AM	FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs (ACCESSWIRE)
Nov-04-24 08:30AM	Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS) (ACCESSWIRE)
Oct-29-24 10:00AM	Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting (ACCESSWIRE)
Oct-16-24 08:30AM	Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S. (ACCESSWIRE) +6.03%
Oct-11-24 04:15PM	Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (ACCESSWIRE)
Oct-10-24 10:00AM	Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum (ACCESSWIRE)
Oct-09-24 06:16PM	Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ... (GuruFocus.com)
Oct-08-24 08:30AM	Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial (ACCESSWIRE)
Oct-02-24 06:52AM	Jaguars diarrhoea drug shows benefit in Phase III breast cancer subgroup (Clinical Trials Arena) +8.13%

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Cyber Swan Sale

50% Off Elite

JAGX

Jaguar Health Inc

Upgrade your FINVIZ experience